Skip to Content

Notice

Guidance Documents Related to Coronavirus Disease 2019 (COVID-19); Availability

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice of availability.

SUMMARY:

The Food and Drug Administration (FDA or Agency) is announcing the availability of FDA guidance documents related to the Coronavirus Disease 2019 (COVID-19) public health emergency (PHE). This notice is pursuant to the process that FDA announced, in the Federal Register of March 25, 2020, for making available to the public COVID-19-related guidances. The guidances identified in this notice address issues related to the COVID-19 PHE and have been issued in accordance with the process announced in the March 25, 2020, document. The guidance documents have been implemented without prior comment, but they remain subject to comment in accordance with the Agency's good guidance practices.

DATES:

The announcement of the guidances is published in the Federal Register on May 12, 2020. The guidance documents have been implemented without prior comment, but they remain subject to comment in accordance with the Agency's good guidance practices.

ADDRESSES:

You may submit either electronic or written comments on Agency guidances at any time as follows:Start Printed Page 28011

Electronic Submissions

Submit electronic comments in the following way:

  • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.
  • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submissions as follows:

  • Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
  • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the name of the guidance document that the comments address and the docket number for the guidance (see table 1). Received comments will be placed in the docket(s) and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.

  • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/​content/​pkg/​FR-2015-09-18/​pdf/​2015-23389.pdf.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

You may submit comments on any guidance at any time (see § 10.115(g)(5) (21 CFR 10.115(g)(5))).

Submit written requests for single copies of any of these guidances to the addresses noted in table 1. Where applicable, send two self-addressed adhesive labels to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Stephen Ripley, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911; Erica Takai, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5456, Silver Spring, MD 20993-0002, 301-796-6353; Phil Chao, Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-2112; Kimberly Thomas, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6220, Silver Spring, MD 20993-0002, 301-796-2357; Diane Heinz, Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-402-5692.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

I. Background

On January 31, 2020, as a result of confirmed cases of COVID-19, and after consultation with public health officials as necessary, Alex M. Azar II, Secretary of Health and Human Services (HHS), pursuant to the authority under section 319 of the Public Health Service Act (PHS Act) (42 U.S.C. 247d), determined that a PHE exists and has existed since January 27, 2020, nationwide.[1] On March 13, 2020, President Donald J. Trump declared that the COVID-19 outbreak in the United States constitutes a national emergency, beginning March 1, 2020.[2]

In the Federal Register of March 25, 2020 (85 FR 16949) (the March 25, 2020, notice) (available at: https://www.govinfo.gov/​content/​pkg/​FR-2020-03-25/​pdf/​2020-06222.pdf), FDA announced procedures for making available FDA guidance documents related to the COVID-19 PHE. These procedures, which operate within FDA's established good guidance practices regulations, are intended to allow FDA to rapidly disseminate Agency recommendations and policies related to COVID-19 to industry, FDA staff, and other stakeholders. The March 25, 2020, notice stated that due to the need to act quickly and efficiently to respond to the COVID-19 PHE, FDA believes that prior public participation will not be feasible or appropriate before FDA implements COVID-19-related guidance documents. Therefore, FDA will issue COVID-19-related guidance documents for immediate implementation without prior public comment (see section 701(h)(1)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 371(h)(1)(C) and § 10.115(g)(2)). The guidances are available on FDA's web page “COVID-19-Related Guidance Documents for Industry, FDA Staff, and Other Stakeholders” (https://www.fda.gov/​emergency-preparedness-and-response/​mcm-issues/​covid-19-Start Printed Page 28012related-guidance-documents-industry-fda-staff-and-other-stakeholders) and through FDA's web page “Search for FDA Guidance Documents” (https://www.fda.gov/​regulatory-information/​search-fda-guidance-documents).

The March 25, 2020, notice further stated that, in general, rather than publishing a separate notice of availability (NOA) for each COVID-19-related guidance document, FDA intends to publish periodically a consolidated NOA announcing the availability of COVID-19-related guidance documents FDA issued during the relevant period. This notice announces certain COVID-19-related guidances that are posted on FDA's website, as included in table 1.

Lastly, the March 25, 2020, notice indicated that, in general, guidance documents would be placed in dockets established for COVID-19-related guidance documents issued by each Center. As noted in table 1, certain COVID-19-related guidance documents issued by the Center for Drug Evaluation and Research (CDER) prior to March 24, 2020, were placed in Docket No. FDA-2020-D-1106. FDA anticipates that, in general, CDER will use Docket No. FDA-2020-D-1136 for additional COVID-19-related guidance documents issued pursuant to the process described in the March 25, 2020, notice.

II. Availability of COVID-19-Related Guidance Documents

Pursuant to the process described in the March 25, 2020, notice, FDA is announcing the availability of the following COVID-19-related guidance documents:

Table 1— Guidances Related to the COVID-19 Public Health Emergency

Docket No.Center/officeTitle of guidanceContact information to request single copies
FDA-2020-D-1137Center for Biologics Evaluation and Research (CBER)Alternative Procedures for Blood and Blood Components During the COVID-19 Public Health Emergency (April 2020)Office of Communication, Outreach and Development, Center for Biologics Evaluation and Research, 10903 New Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993-0002, 1-800-835-4709 or 240-402-8010; email ocod@fda.hhs.gov.
FDA-2020-D-1138Center for Devices and Radiological Health (CDRH)Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring During the Coronavirus Disease-2019 (COVID-19) Public Health Emergency (March 2020)CDRH-Guidance@fda.hhs.gov. Please include the document number 20014 and complete title of the guidance in the request.
FDA-2020-D-1138CDRHEnforcement Policy for Ventilators and Accessories and Other Respiratory Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (March 2020)CDRH-Guidance@fda.hhs.gov. Please include the document number 20015 and complete title of the guidance in the request.
FDA-2020-D-1138CDRHEnforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (March 2020)CDRH-Guidance@fda.hhs.gov Please include the document number 20019 and complete title of the guidance in the request.
FDA-2020-D-1138CDRHEnforcement Policy for Gowns, Other Apparel, and Gloves During the Coronavirus Disease (COVID-19) Public Health Emergency (March 2020)CDRH-Guidance@fda.hhs.gov Please include the document number 20020 and complete title of the guidance in the request.
FDA-2020-D-1138CDRHEnforcement Policy for Face Masks and Respirators During the Coronavirus Disease (COVID-19) Public Health Emergency (Issued March 25, 2020) (Revised April 2, 2020)CDRH-Guidance@fda.hhs.gov. Please include the document number 20018 and complete title of the guidance in the request.
FDA-2020-D-1139Center for Food Safety and Applied Nutrition (CFSAN)Temporary Policy Regarding Nutrition Labeling of Certain Packaged Food During the COVID-19 Public Health Emergency (March 2020)Office of Nutrition and Food Labeling, Food Labeling and Standards Staff, Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740.
FDA-2020-D-1139CFSANTemporary Policy Regarding Nutrition Labeling of Standard Menu Items in Chain Restaurants and Similar Retail Food Establishments During the COVID-19 Public Health Emergency (April 2020)Office of Nutrition and Food Labeling, Food Labeling and Standards Staff, Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740.
FDA-2020-D-1139CFSANTemporary Policy Regarding Packaging and Labeling of Shell Eggs Sold by Retail Food Establishments During the COVID-19 Public Health Emergency (April 2020)Office of Nutrition and Food Labeling, Food Labeling and Standards Staff, Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740.
FDA-2020-D-1106CDERFDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency (March 18, 2020) (Updated March 27, 2020, April 2, 2020, and April 16, 2020)Clinicaltrialconduct-COVID19@fda.hhs.gov. Please include the docket number FDA-2020-D-1106 and complete title of the guidance in the request.
FDA-2020-D-1106CDERTemporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) (March 19, 2020) (Updated March 27, 2020, and April 15, 2020)druginfo@fda.hhs.gov. Please include the docket number FDA-2020-D-1106 and complete title of the guidance in the request.
Start Printed Page 28013
FDA-2020-D-1106CDERPolicy for Certain REMS Requirements During the COVID-19 Public Health Emergency (March 2020)druginfo@fda.hhs.gov. Please include the docket number FDA-2020-D-1106 and complete title of the guidance in the request.
FDA-2020-D-1106CDERTemporary Policy for Manufacture of Alcohol for Incorporation Into Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry (March 24, 2020) (Updated March 27, 2020, and April 15, 2020)druginfo@fda.hhs.gov. Please include the docket number FDA-2020-D-1106 and complete title of the guidance in the request.
FDA-2020-D-1106CDERPolicy for Temporary Compounding of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (March 2020) (Updated April 15, 2020)druginfo@fda.hhs.gov. Please include the docket number FDA-2020-D-1106 and complete title of the guidance in the request.
FDA-2020-D-1140Center for Veterinary Medicine (CVM)CVM GFI #269—Enforcement Policy Regarding Federal VCPR Requirements to Facilitate Veterinary Telemedicine During the COVID-19 Outbreak (March 2020)AskCVM@fda.hhs.gov. Please include the docket number FDA-2020-D-1140 and complete title of the guidance in the request.
FDA-2020-D-1140CVMCVM GFI #270—Guidance on the Conduct and Review of Studies to Support New Animal Drug Development during the COVID-19 Public Health Emergency (April 2020)>AskCVM@fda.hhs.gov. Please include the docket number FDA-2020-D-1140 and complete title of the guidance in the request.

Although these guidance documents have been implemented immediately without prior comment, FDA will consider all comments received and revise the guidances as appropriate (see § 10.115(g)(3)).

III. Significance of Guidances

These guidances are being issued consistent with FDA's good guidance practices regulation (§ 10.115). The guidances represent the current thinking of FDA. They do not establish any rights for any person and are not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.

IV. Paperwork Reduction Act of 1995

A. Center for Biologics Evaluation and Research

This guidance refers to previously approved collections of information. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3521) (PRA). The collections of information in the following FDA regulations and guidance have been approved by OMB as listed in the following table:

COVID-19 guidance title21 CFR Cite referenced in COVID-19 guidanceAnother guidance title referenced in COVID-19 guidanceOMB Control No(s).
Alternative Procedures for Blood and Blood Components During the COVID-19 Public Health Emergency601.12 640.120 part 630N/A0910-0338 0910-0338 0910-0116

B. Center for Devices and Radiological Health

These guidances refer to previously approved collections of information. These collections of information are subject to review by OMB under the PRA. The collections of information in the following FDA regulations and guidance have been approved by OMB as listed in the following table:

COVID-19 guidance title21 CFR Cite referenced in COVID-19 GuidanceAnother guidance title referenced in COVID-19 guidanceOMB Control No(s).
Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring During the Coronavirus Disease-2019 (COVID-19) Public Health Emergency807, subpart E 800, 801, and 8090910-0120 0910-0485
Enforcement Policy for Ventilators and Accessories and Other Respiratory Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency800, 801, and 809 803 807, subpart E 812 8200910-0485 0910-0437 0910-0120 0910-0078 0910-0073
Start Printed Page 28014
Emergency Use Authorization of Medical Products and Related Authorities; Guidance for Industry and Other Stakeholders0910-0595
Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency800, 801, and 809 807, subpart E 807, subparts A through D0910-0485 0910-0120 0910-0625
814, subparts A through E 820 830 and 801.200910-0231 0910-0073 0910-0720
Enforcement Policy for Gowns, Other Apparel, and Gloves During the Coronavirus Disease (COVID-19) Public Health Emergency800, 801, and 809 806 807, subparts A through D0910-0485 0910-0359 0910-0625
807, subpart E 820 830 and 801.200910-0120 0910-0073 0910-0720
Enforcement Policy for Face Masks and Respirators During the Coronavirus Disease (COVID-19) Public Health Emergency (Revised)800, 801, and 809 803 806 807, subpart E 807, subparts A through D0910-0485 0910-0437 0910-0359 0910-0120 0910-0625
820 830 and 801.200910-0073 0910-0720
Emergency Use Authorization of Medical Products and Related Authorities; Guidance for Industry and Other Stakeholders0910-0595

C. Center for Food Safety and Applied Nutrition

These guidances refer to previously approved collections of information. These collections of information are subject to review by OMB under the PRA. The collections of information in the following FDA regulations and guidances have been approved by OMB as listed in the following table:

COVID-19 guidance title21 CFR Cite referenced in COVID-19 guidanceAnother guidance title referenced in COVID-19 guidanceOMB Control No(s).
Temporary Policy Regarding Nutrition Labeling of Standard Menu Items in Chain Restaurants and Similar Retail Food Establishments During the COVID-19 Public Health Emergency101.110910-0782
Temporary Policy Regarding Packaging and Labeling of Shell Eggs Sold by Retail Food Establishments During the COVID-19 Public Health Emergencypart 101Temporary Policy Regarding Nutrition Labeling of Certain Packaged Food During the COVID19 Public Health Emergency; 0910-0381, 0910-07920910-0381

This guidance refers to previously approved collections of information. These collections of information are subject to review by OMB under the PRA. The collections of information in the following FDA regulations and guidance have been approved by OMB as listed in the table below. This guidance also contains a new collection of information not approved under a current collection. This new collection of information has been granted a PHE waiver from the PRA by HHS on March 19, 2020, under section 319(f) of the PHS Act. Information concerning the PHE PRA waiver can be found on the HHS website at https://aspe.hhs.gov/​public-health-emergency-declaration-pra-waivers. Start Printed Page 28015

COVID-19 guidance title21 CFR Cite referenced in COVID-19 guidanceAnother guidance referenced in COVID-19 guidanceOMB Control No(s).New collection covered by PHE PRA waiver
Temporary Policy Regarding Nutrition Labeling of Certain Packaged Food During the COVID-19 Public Health Emergencypart 101; section 403(w) of the FD&C Act (21 U.S.C. 343(w))0910-0381, 0910-0792If a food product does not have the required labeling information, a restaurant may create a label to include this information (new respondent).

D. Center for Drug Evaluation and Research

This guidance refers to previously approved collections of information. These collections of information are subject to review by OMB under the PRA. The collections of information in the following FDA regulations and guidances have been approved by OMB as listed in the following table:

COVID-19 guidance title21 CFR Cite referenced in COVID-19 guidanceAnother guidance referenced in COVID-19 guidanceOMB Control No(s).
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency (Updated)50.27(a) 312.30 312.60 312.62 812.35(a) 812.140Use of Electronic Informed Consent in Clinical Investigations0910-0001 0910-0014 0910-0755

These guidances refer to previously approved collections of information. These collections of information are subject to review by OMB under the PRA. The collections of information in the following FDA regulations and guidance have been approved by OMB as listed in the table below. These guidances also contain a new collection of information not approved under a current collection. This new collection of information has been granted a PHE waiver from the PRA by HHS on March 19, 2020, under section 319(f) of the PHS Act. Information concerning the PHE PRA waiver can be found on the HHS website at https://aspe.hhs.gov/​public-health-emergency-declaration-pra-waivers.

COVID-19 guidance title21 CFR Cite referenced in COVID-19 guidanceAnother guidance referenced in COVID-19 guidanceOMB Control No(s).New collection covered by PHE PRA waiver
Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)Policy for Temporary Compounding of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency Temporary Policy for Manufacture of Alcohol for Incorporation Into Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Providing Regulatory Submissions in Electronic Format—Drug Establishment Registration and Drug Listing Postmarketing Adverse Event Reporting for Nonprescription Human Drug Products Marketed Without an Approved Application0910-0045 0910-0139 0910-0230 0910-0291 0910-0340 0910-0641 0910-0645 0910-0800For proposed use of an alternative grade of ethanol, firms are requested to submit to FDA information on the ethanol concentration and levels of impurities listed in the USP monograph and other potentially harmful impurities in the manufacturing environment.
Start Printed Page 28016
Policy for Temporary Compounding of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (Updated)Current Good Manufacturing Practices for Finished Pharmaceuticals and Medical Gases Postmarketing Adverse Drug Experience Reporting MedWatch: Adverse Event and Product Experience Reporting System (Paper-Based) Format and Content Requirements for Over-the-Counter Drug Product Labeling FDA Adverse Event and Product Experience Reports; Electronic Submissions Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Temporary Policy for Manufacture of Alcohol for Incorporation Into Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)0910-0139 0910-0230 0910-0291 0910-0340 0910-0645For proposed use of an alternative grade of ethanol, firms are requested to submit to FDA information on the ethanol concentration and levels of impurities listed in the USP monograph and other potentially harmful impurities in the manufacturing environment.
Temporary Policy for Manufacture of Alcohol for Incorporation Into Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)Policy for Temporary Compounding of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Providing Regulatory Submissions in Electronic Format—Drug Establishment Registration and Drug Listing0910-0045 0910-0139 0910-0230 0910-0291 0910-0340 0910-0641 0910-0645For proposed use of an alternative grade of ethanol, firms are requested to submit to FDA information on the ethanol concentration and levels of impurities listed in the USP monograph and other potentially harmful impurities in the manufacturing environment.

The final guidance entitled “Policy for Certain REMS Requirements During the COVID-19 Public Health Emergency” contains no collection of information. Therefore, clearance by OMB under the PRA is not required.

E. Center for Veterinary Medicine

This guidance refers to previously approved collections of information. These collections of information are subject to review by OMB under the PRA. The collections of information in the following FDA regulations and guidance have been approved by OMB as listed in the following table:

COVID-19 guidance title21 CFR Cite referenced in COVID-19 guidanceAnother guidance title referenced in COVID-19 guidanceOMB Control No(s).
GFI #270—Guidance on the Conduct and Review of Studies to Support New Animal Drug Development during the COVID-19 Public Health EmergencyFDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency0910-0032 0910-0669

The final guidance entitled “GFI #269—Enforcement Policy Regarding Federal VCPR Requirements to Facilitate Veterinary Telemedicine During the COVID-19 Outbreak” contains no collection of information. Therefore, clearance by OMB under the PRA is not required.

V. Electronic Access

Persons with access to the internet may obtain COVID-19-related guidances at the FDA web page “COVID-19-Related Guidance Documents for Industry, FDA Staff, and Other Stakeholders,” available at https://www.fda.gov/​emergency-preparedness-and-response/​mcm-issues/​covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders;​ the FDA web page “Search for FDA Guidance Documents,” available at https://www.fda.gov/​regulatory-information/​search-fda-guidance-documents;​ or https://www.regulations.gov.

Start Signature

Dated: May 7, 2020.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.

End Signature End Supplemental Information

Footnotes

1.  On April 21, 2020, the PHE Determination was extended, effective April 26, 2020. These PHE Determinations are available at https://www.phe.gov/​emergency/​news/​healthactions/​phe/​Pages/​default.aspx.

Back to Citation

2.  Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (March 13, 2020), available at https://www.whitehouse.gov/​presidential-actions/​proclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak/​.

Back to Citation

[FR Doc. 2020-10146 Filed 5-11-20; 8:45 am]

BILLING CODE 4164-01-P